Trial · NCT02232880
Treatment of Resistant Hypertension by Prevention of T-Cell Co-Stimulation
NCT02232880, Phase 2, Terminated, Vanderbilt University Medical Center; results first posted 2016-08-29
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Treatment of Resistant Hypertension by Prevention of T-Cell Co-Stimulation. Trials, record NCT02232880. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02232880
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Treatment of Resistant Hypertension by Prevention of T-Cell Co-Stimulation
- NCT number
- NCT02232880
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 1 participants, actual
- Lead sponsor
- Vanderbilt University Medical Center
- Conditions
- Hypertension
- Interventions
- Abatacept, Placebo
- First posted
- 2014-09-05
- Last updated
- 2017-02-07
- Results first posted
- 2016-08-29
- Limitations and caveats
- No patients received treatment prior to study termination.
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Systolic Blood Pressure From Randomization to End of Treatment | 6 months | Ambulatory blood pressure monitoring will be used at the end of the 4 weeks standardized treatment and at the end of 6 months randomized treatment with abatacept or placebo. The change in systolic blood pressure from these 2 recordings will be the primary endpoint. |
| Secondary | Change in Blood Pressure | 6 months | Changes in the rate of change of blood pressure estimated by automated in office cuff measurements and ambulatory blood pressure at 12 weeks after randomization |
| Secondary | Change in Brachial Artery Reactivity | 6 months | change in brachial artery reactivity measured at randomization and after 24 weeks of treatment |
| Secondary | Change in Inflammatory Markers | 6 months | changes in plasma and T cell markers of activation and T cell cytokine production from randomization to end of 24 weeks of treatment |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change in Systolic Blood Pressure From Randomization to End of Treatment | 6 months | No patients received treatment prior to study termination | ||
| SECONDARY | Change in Blood Pressure | 6 months | No patients received treatment prior to study termination. | ||
| SECONDARY | Change in Brachial Artery Reactivity | 6 months | No patients received treatment prior to study termination | ||
| SECONDARY | Change in Inflammatory Markers | 6 months | No patients received treatment prior to study termination |
Source ClinicalTrials.gov
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Consented Patients | 1 | |
| Overall Study | COMPLETED | Consented Patients | 0 | |
| Overall Study | NOT COMPLETED | Consented Patients | 1 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Consented Patients | ||
| Total, other adverse events | Consented Patients | 0 | 1 |
| Total, serious adverse events | Consented Patients | 0 | 1 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02232880
GET https://conductscience.org/api/trials/v1/NCT02232880/registered